The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer.
 
Michael J. Morris
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Amgen; AstraZeneca; Clarity Pharmaceuticals; Convergent Therapeutics; Daiichi; Exelixis; ITM Isotope Technologies Munich; Lantheus Medical Imaging; NCCN; Pfizer
Research Funding - Bayer (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Janssen (Inst); Novartis (Inst); Progenics (Inst); Roche/Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - Bayer; Janssen Oncology; Novartis
 
Mark David Linch
Consulting or Advisory Role - ADC Therapeutics; Astellas Pharma; AstraZeneca; Bicycle Therapeutics; BioNTech; Bristol-Myers Squibb; Janssen Oncology; Pfizer/EMD Serono
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Shionogi (Inst)
Travel, Accommodations, Expenses - bristol myers squibb; Janssen; MSD
 
Simon J. Crabb
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Merck; Pfizer
Consulting or Advisory Role - Amphista Therapeutics; Astellas Pharma; AstraZeneca; Bayer; EMD Serono; Janssen; Merck; Novartis; Pfizer; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca; Clovis Oncology; Roche
Expert Testimony - Merck/Pfizer; MSD
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Janssen; Merck; Merck
 
Tomasz M. Beer
Employment - Exact Sciences
Stock and Other Ownership Interests - Arvinas; Exact Sciences; Salarius Pharmaceuticals
Consulting or Advisory Role - Abbvie; Amgen; Arvinas; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Dantari Pharmaceuticals; GlaxoSmithKline; GRAIL; Janssen; Pfizer; Sanofi; Sapience Therapeutics
Research Funding - Alliance Foundation Trials (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Freenome (Inst); GRAIL (Inst); Harpoon Therapeutics (Inst); Janssen Research & Development (Inst); Medivation (Inst); Sotio (Inst); Theraclone Sciences (Inst); Zenith Epigenetics (Inst)
 
Elisabeth I. Heath
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Caris Life Sciences; Genzyme; Janssen; Johnson & Johnson/Janssen; Sanofi; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Sanofi; Seagen
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); AIQ Solutions (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Calithera Biosciences (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Champions Oncology (Inst); Corcept Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curemeta (Inst); Daiichi Sankyo Inc. (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Esanik (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen Research & Development (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Pellficure (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Pfizer (Inst); Pharmacyclics (Inst); Plexxikon (Inst); POINT Biopharma (Inst); Roche (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
Other Relationship - Caris Centers of Excellence
 
Michael S. Gordon
Stock and Other Ownership Interests - BeckonCall; Caremission; WCCT Global
Consulting or Advisory Role - Imaging Endpoints; Morphic Therapeutic; Qualigen Therapeutics; Viracta Therapeutics
Research Funding - AADi (Inst); Abbvie (Inst); Advaxis (Inst); Agenus (Inst); Alpine Immune Sciences (Inst); Amal Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Athenex (Inst); Ayala Pharmaceuticals (Inst); Beigene (Inst); BeiGene (Inst); BioEclipse Therapeutics (Inst); BiolineRx (Inst); BiolineRx (Inst); BioNTech (Inst); BioXCel therapeutics (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Caris Centers of Excellence (Inst); Celgene (Inst); Celldex (Inst); Codiak Biosciences (Inst); Coordination Therapeutics (Inst); Corcept Therapeutics (Inst); Deciphera (Inst); Dracen (Inst); Driver Group (Inst); DynamiCure Biotechnology (Inst); Elevation Oncology (Inst); Endocyte (Inst); Faeth Therapeutics (Inst); FibroGen (Inst); Fore Biotherapeutics (Inst); FORMA Therapeutics (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); Genentech/Roche (Inst); Genzada Pharmaceuticals (Inst); Genzada Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HCW Biologics (Inst); Helix BioPharma (Inst); Helix BioPharma (Inst); HiberCell (Inst); I-Mab (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); IgM Biosciences (Inst); ImaginAb (Inst); ImaginAb (Inst); ImmuneSensor Therapeutics (Inst); ImmuneSensor Therapeutics (Inst); Inanovate (Inst); Incyte (Inst); Inhibrx (Inst); InhibRx (Inst); Intra ImmuSG (Inst); Istari Oncology (Inst); Jubilant Therapeutics (Inst); Lilly/ImClone (Inst); MabVax (Inst); MabVax (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Minneamrita Therapeutics (Inst); Molecular Partners (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Nimbus Therapeutics (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); OncoResponse (Inst); PEEL Therapeutics (Inst); Pfizer (Inst); Pionyr (Inst); Pionyr (Inst); Plexxikon (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Riboscience (Inst); Rubius Therapeutics (Inst); Salarius Pharmaceuticals (Inst); Salarius Pharmaceuticals (Inst); Samumed (Inst); Seagen (Inst); Seattle Genetics/Astellas (Inst); Senhwa Biosciences (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Sirnaomics (Inst); Syndax (Inst); Syndax (Inst); Synthorx (Inst); Theseus Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); TRACON Pharma (Inst); Trishula Therapeutics (Inst); TTC Oncology (Inst); TTC Oncology (Inst); Vedanta Biosciences (Inst); Veru (Inst); Y-mAbs Therapeutics (Inst); Zai Lab (Inst)
Patents, Royalties, Other Intellectual Property - Patient on patient selection for Clinical Trials
 
Johann S. De Bono
Employment - Institute of Cancer Research
Honoraria - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; BioExcel; Boehringer Ingelheim; Celgene; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Medivation; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Novartis; Orion; Pfizer; Qiagen; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Research Funding - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; CellCentric; Daiichi Sankyo; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Vertex
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Cellcentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
 
Hristina I Pashova
Employment - Corcept Therapeutics
Stock and Other Ownership Interests - Corcept Therapeutics
 
Iulia Cristina Tudor
Employment - Corcept Therapeutics
Stock and Other Ownership Interests - Corcept Therapeutics
Patents, Royalties, Other Intellectual Property - Corcept Therapeutics
 
Andrew E Greenstein
Employment - Corcept Therapeutics
Stock and Other Ownership Interests - Corcept Therapeutics
Patents, Royalties, Other Intellectual Property - Corcept Therapeutics
 
Grace Mann
Employment - Corcept Therapeutics
 
Glenn Liu
Employment - AIQ Solutions
Leadership - AIQ Solutions
Stock and Other Ownership Interests - AIQ Solutions
Consulting or Advisory Role - Janssen medical Affairs
Research Funding - Johnson & Johnson (Inst); Madison Vaccines, Inc.; Novartis (Inst); Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - I have patent pending titled "System and method for evaluation of disease burden" which provides a novel method to identify and quantitate treatment response. (Inst)